Top Markets
Coin of the day
Psyence Biomedical Ltd. Psyence Biomedical Ltd.

Psyence Biomedical Ltd.

PBM
Peringkat dalam Saham #40932
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines... Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Harga Saham
$3.20
Terakhir disinkronkan: 2026-07-31
Kapitalisasi Pasar
$60.86K
Perubahan (1 hari)
-4.76%
Perubahan (1 tahun)
-83.44%
Negara
CA
Perdagangan Psyence Biomedical Ltd. (PBM)

Kategori

Laba untuk Psyence Biomedical Ltd. (PBM)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Psyence Biomedical Ltd., laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Psyence Biomedical Ltd. dari 2026 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE